kabutan

Eisai Co., Ltd.(4523) Summary

4523
TSE Prime
Eisai Co., Ltd.
4,605
JPY
+35
(+0.77%)
Apr 28, 3:30 pm JST
28.92
USD
Apr 28, 2:30 am EDT
Result
PTS
outside of trading hours
4,532
Apr 28, 9:57 pm JST
Summary Chart Historical News Financial Result
PER
31.3
PBR
1.46
Yield
3.47%
Margin Trading Ratio
19.70
Stock Price
Apr 28, 2026
Opening Apr 28, 9:00 am
4,634 JPY 29.07 USD
Previous Close Apr 27
4,570 JPY 28.67 USD
High Apr 28, 9:00 am
4,635 JPY 29.08 USD
Low Apr 28, 1:04 pm
4,539 JPY 28.51 USD
Volume
1,147,300
Trading Value
5.26B JPY 0.03B USD
VWAP
4586.92 JPY 28.81 USD
Minimum Trading Value
460,500 JPY 2,892 USD
Market Cap
1.34T JPY 8.45B USD
Number of Trades
2,637
Liquidity & Number of Trades
As of Apr 28, 2026
Liquidity
High
1-Year Average
3,534
1-Year High May 15, 2025
11,589
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 47,500 908,800 19.13
Apr 17, 2026 63,700 796,600 12.51
Apr 10, 2026 75,000 747,300 9.96
Apr 3, 2026 68,000 774,800 11.39
Mar 27, 2026 163,000 825,500 5.06
Company Profile
Eisai Co., Ltd. is a major pharmaceutical company with strengths in neurology and gastrointestinal oncology. The company has expanded into the field of dementia treatments.
Sector
Pharmaceuticals
Eisai's pharmaceutical business accounts for 90% of its sales, encompassing research and development, manufacturing, and sales of both prescription and over-the-counter medicines. The company has a strong global presence with a high overseas sales ratio. Outside Japan, Eisai operates in North America, China, EMEA (Europe, Middle East, Africa, Russia, and Oceania), and Asia-Latin America (South Korea, Taiwan, India, ASEAN, and Latin America). Internationally, Eisai conducts business through its subsidiaries in various regions. In Japan, the company collaborates with group companies such as KAN Research Institute and EA Pharma to advance its operations. In the United States, Eisai markets an Alzheimer's disease treatment that gained attention as the world's first medication to demonstrate a reduction in early clinical symptom progression during clinical trials. Leveraging its global research and development infrastructure and sales network, Eisai aims to provide pharmaceuticals that meet the needs of patients worldwide.